Quinuclidinol Derivatives for Reduced Systemic Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current muscarinic receptor antagonists used to treat respiratory disorders like asthma and COPD have significant systemic side effects and require frequent dosing due to short duration of action, leading to inconvenient treatment regimens and potential non-compliance.
Innovation Solution
Development of novel N-linked-heterocycle-substituted alkyl esters of polycyclic amino alcohols that act as potent muscarinic receptor antagonists with reduced systemic side effects and extended duration of action, allowing for once or twice daily dosing when administered by inhalation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If muscarinic receptor antagonists are administered by inhalation to treat respiratory disorders, then the therapeutic effect on airways is improved, but significant systemic absorption occurs resulting in side effects such as dry mouth
Solution Approach 1:
The patent modifies the chemical structure of muscarinic receptor antagonists by introducing specific molecular features (such as the N-linked heterocycle and polycyclic amino alcohol framework) that alter the drug's pharmacokinetic properties. These structural parameter changes reduce systemic absorption while maintaining bronchodilator activity, thereby reducing side effects like dry mouth while preserving therapeutic effect.
2Ease of manufacture
If muscarinic receptor antagonists with short duration of action are used, then the compounds are simpler and easier to synthesize, but multiple daily dosing is required which is inconvenient and creates compliance risks
Solution Approach 1:
The patent develops compounds with extended duration of action through optimized molecular structures that maintain stable receptor binding. The dynamic property of prolonged pharmacological activity allows once or twice daily dosing, improving patient compliance while the synthetic routes remain practical for manufacturing.
3Reliability
If frequent repeat dosing is required, then the treatment can maintain therapeutic levels, but patient compliance decreases due to inconvenience and risk of inadequate treatment
Solution Approach 1:
The patent creates compounds with extended duration of action that maintain continuous therapeutic effect throughout the dosing interval. This continuous pharmacological activity ensures sustained bronchodilator effect while reducing dosing frequency to once or twice daily, thereby improving patient compliance without compromising therapeutic level maintenance.
Data Source
Figure 1~3
AI summary
The invention provides compounds of formula (I) wherein R5 is a group of formula (II) or (III) and R1, R2, R3, R4, R6, a, b, Z, Y and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharmaceutical compositions, their use in therapy and intermediates of use in their preparation.